Comparative clinical and laboratory study of rivaroxaban and its generic forms in patients with stable coronary artery disease
https://doi.org/10.15829/1560-4071-2025-6286
EDN: TEWITO
Abstract
The course and complications of coronary artery disease (CAD) are associated with atherosclerosis progression and a high probability of atherothrombosis. Antithrombotic therapy is the most effective strategy for preventing cardiovascular events in atherosclerotic diseases. In accordance with current clinical guidelines for the prevention of myocardial infarction and stroke, all patients with stable CAD are recommended to take acetylsalicylic acid (ASA). In patients with a high risk of ischemic events without a high risk of bleeding, addition of low dose anticoagulant rivaroxaban to ASA is possible. The article discusses the design of a clinical and laboratory prospective single-center comparative study, the purpose of which is to compare the efficacy and safety of two following bioequivalent agents: the original (Xarelto, AO Bayer, Germany) and generic (Kruoksaban, OOO Ozon LLC, Russia) rivaroxaban.
About the Authors
N. V. Lomakin
Central Clinical Hospital with a Polyclinic of the Administrative Directorate of the President of the Russian Federation; Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
none
I. Yu. Tkach
Central Clinical Hospital with a Polyclinic of the Administrative Directorate of the President of the Russian Federation; Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
none
E. A. Shirokov
Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
none
References
1. Healthcare in Russia. 2023: Stat. sb./Rosstat. М., З-46 2023. 179 с. (In Russ.). п. 2023: Стат. сб./Росстат. М., З-46 2023. 179 с.
2. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(10):973-1003. doi:10.1016/S1474-4422(24)00369-7.
3. Wang Y, Haddad Y, Patel R, et al. Factors influencing the outcome of cardiogenic cerebral embolism: a literature review. Neurol Res. 2022;44(3):187-95. doi:10.1080/01616412.2021.1968704.
4. Barbarash OL, Karpov YuA, Panov AV, et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) doi:10.15829/1560-4071-2024-6110. EDN HHJJUT.
5. Steffel J, Eikelboom JW, Anand S, et al. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020;142(1):40-8. doi:10.1161/CIRCULATIONAHA.120.046048.
6. Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic. an economic analysis of atrial fibrillation in the UK. Heart. 2004;90:286-92.
7. Boytsov SA, Lukyanov MM, Yakushin SS, Martsevich SY. Register of cardiovascular diseases (RECVAZA): Diagnosis, treatment, combined cardiovascular pathology and concomitant diseases in patients with atrial fibrillation in real outpatient practice. Cardiovascular Therapy and Prevention. 2014;13(6):44-50. (In Russ.)
- All patients with stable coronary artery disease and a high risk of ischemic events without a high risk of bleeding are recommended to consider adding a second antiplatelet agent or the anticoagulant rivaroxaban at a dose of 2,5 mg 2 times a day to acetylsalicylic acid.
- Laboratory effects reflecting the hemostasis status and pharmacodynamics of the original rivaroxaban (Xarelto, AO Bayer, Germany) at a dose of 2,5 mg 2 times a day and generic rivaroxaban (Kruoksaban, Ozon LLC, Russia) will be studied.
Review
For citations:
Lomakin N.V., Tkach I.Yu., Shirokov E.A. Comparative clinical and laboratory study of rivaroxaban and its generic forms in patients with stable coronary artery disease. Russian Journal of Cardiology. 2025;30(2):6286. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6286. EDN: TEWITO
Views:
339
Email this article 